NCT06640257进行中（未招募）3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of SHR-1314 Injection in Adults With Active Psoriatic Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 208
- 试验地点
- 1
- 主要终点
- Proportion of subjects achieving ACR 20 improvement at week 24
研究概览
简要总结
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject voluntarily signs an informed consent form before any procedures related to the research start;
- •At the time of screening, it met the 2006 psoriatic arthritis classification standard (CASPAR)；
- •There is active PsA before randomization;
- •Have active plaque psoriasis (at least one plaque skin lesion) at the time of screening, or have a history of plaque psoriasis;
- •Participants who have previously been treated with csDMARDs and/or NSAIDs still have active psoriatic arthritis disease.
排除标准
- •Existence of any of the following medical history or comorbid diseases: drug-induced psoriasis; other active inflammatory diseases or autoimmune diseases; history of organ transplantation; history of lymphocytic proliferation; severe infections, etc.
- •Have received psoriatic arthritis or psoriasis drugs, such as intra-articular injections, plant preparations, etc. within a certain period of time in the past.
- •Those who are allergic to the drug ingredients or excipients in this study, or are allergic to other biological agents.
- •A history of alcohol abuse or illegal drug abuse in pregnant or breastfeeding women, etc.
研究组 & 干预措施
SHR-1314 injection
Experimental
干预措施: SHR-1314 injection (Drug)
placebo
Placebo Comparator
干预措施: SHR-1314 injection (Drug)
placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of subjects achieving ACR 20 improvement at week 24
时间窗: Week 24
次要结局
- The proportion of subjects who achieved ACR 50 improvement(Week 24)
- The proportion of subjects who achieved ACR 70 improvement(Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPsoriasisNCT06477237Huabo Biopharm Co., Ltd.400
已完成
3 期
Efficacy and Safety of MW031 in PMO SubjectsOsteoporosis, PostmenopausalNCT05215977Mabwell (Shanghai) Bioscience Co., Ltd.448
Unknown
3 期
Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminType 2 Diabetes MellitusNCT02477969Jiangsu Hansoh Pharmaceutical Co., Ltd.587
已完成
3 期
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseType 2 DiabetesNCT05628311Innovent Biologics (Suzhou) Co. Ltd.319
招募中
3 期
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Advanced Breast CancerFemale Breast CancerNCT05439499Ahon Pharmaceutical Co., Ltd.434